<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">701286</article-id><article-id pub-id-type="doi">10.17816/dv701286</article-id><article-id pub-id-type="edn">OYPYJO</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hyperandrogenism in dermatology: pathogenesis, diagnosis, and treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Гиперандрогения в дерматологии: патогенез, диагностика и терапевтические стратегии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1259-5454</contrib-id><contrib-id contrib-id-type="spin">7151-1822</contrib-id><name-alternatives><name xml:lang="en"><surname>Zybareva</surname><given-names>Alina S.</given-names></name><name xml:lang="ru"><surname>Зыбарева</surname><given-names>Алина Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alinaziba@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4837-8489</contrib-id><contrib-id contrib-id-type="spin">2330-2758</contrib-id><name-alternatives><name xml:lang="en"><surname>Perlamutrov</surname><given-names>Yuri N.</given-names></name><name xml:lang="ru"><surname>Перламутров</surname><given-names>Юрий Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>mgmsu-skin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6595-1825</contrib-id><contrib-id contrib-id-type="spin">1809-7581</contrib-id><name-alternatives><name xml:lang="en"><surname>Klyuchnikova</surname><given-names>Dina E.</given-names></name><name xml:lang="ru"><surname>Ключникова</surname><given-names>Дина Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>dina_kl@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian University of Medicine</institution></aff><aff><institution xml:lang="ru">Российский университет медицины</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-04-06" publication-format="electronic"><day>06</day><month>04</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-05-17" publication-format="electronic"><day>17</day><month>05</month><year>2026</year></pub-date><volume>29</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>180</fpage><lpage>190</lpage><history><date date-type="received" iso-8601-date="2026-01-19"><day>19</day><month>01</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-09"><day>09</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Эко-Вектор</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-05-17"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/701286">https://rjsvd.com/1560-9588/article/view/701286</self-uri><abstract xml:lang="en"><p>The etiopathogenesis of hyperandrogenism in women has recently received considerable attention, given its relevance and significance in modern dermatology. Elevated androgen levels are associated with a variety of skin changes, such as androgenetic alopecia, acne, and hirsutism, which affect quality of life. These symptoms not only cause physical discomfort but also frequently result in reproductive dysfunction and psychoemotional disorders, impairing overall well-being and social adjustment. There are currently no specific guidelines for treating women with symptoms of hyperandrogenism, making standardized therapy difficult.</p> <p>This review summarizes recent publications on the pathogenesis, clinical signs, diagnosis, and treatment of hyperandrogenism in women, with an emphasis on skin manifestations (acne, androgenetic alopecia, hirsutism), their pathogenesis, diagnosis, and therapeutic strategies. These multifaceted conditions with diverse skin manifestations and complex clinical presentation require a deep understanding of etiopathogenesis and clinical features, necessitating a personalized, interdisciplinary approach to the diagnosis and treatment of hyperandrogenism in women.</p> <p>The work includes reviews, guidelines, original studies, and case reports published in the recent decade in leading databases (PubMed, MEDLINE, UpToDate) and websites (eLIBRARY.RU, disserCat.ru, Cochrane Library, Scopus).</p></abstract><trans-abstract xml:lang="ru"><p>В последние годы особое внимание уделяется изучению этиопатогенетических особенностей гиперандрогенных состояний у женщин, что обусловлено их актуальностью и значимостью в современной дерматологии. Повышенный уровень андрогенов сопровождается рядом кожных изменений, таких как андрогенетическая алопеция, акне и гирсутизм, которые существенно влияют на качество жизни пациенток. Эти проявления не только вызывают физический дискомфорт, но и нередко приводят к нарушению репродуктивной функции, психоэмоциональным расстройствам, ухудшая общее самочувствие и социальную адаптацию пациентов. В настоящее время лечение женщин с симптомами гиперандрогении представляет собой сложную задачу, поскольку нет отдельного свода медицинских рекомендаций, посвящённых исключительно гиперандрогении, что затрудняет стандартизированный подход к лечению.</p> <p>Новизна данного обзора состоит в систематическом объединении современных данных по патогенезу, клиническим проявлениям, диагностике и лечению гиперандрогенных состояний у женщин, для чего выполнен анализ литературы по теме гиперандрогении с акцентом на дерматологические проявления (акне, андрогенетическая алопеция, гирсутизм), патогенез, подходы к диагностике и лечению. Обобщённые данные свидетельствуют, что такие состояния являются многофакторной патологией с разнообразной дерматологической и общей клинической картиной, что требует глубокого понимания этиопатогенеза, знания клинических форм, персонализированного и междисциплинарного подхода к диагностике и лечению гиперандрогении у женщин.</p> <p>В работу включены обзоры, клинические руководства, оригинальные исследования и клинические случаи, опубликованные за последние 10 лет в ведущих базах данных (PubMed, Medline, UpToDate) и интернет-ресурсах (eLibrary, disserCat.ru, Cochrane Library и Scopus).</p></trans-abstract><kwd-group xml:lang="en"><kwd>hyperandrogenism</kwd><kwd>hyperandrogenic conditions</kwd><kwd>acne</kwd><kwd>hirsutism</kwd><kwd>androgenetic alopecia</kwd><kwd>polycystic ovary syndrome</kwd><kwd>androgens</kwd><kwd>combined oral contraceptives</kwd><kwd>antiandrogens</kwd><kwd>review</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гиперандрогения</kwd><kwd>гиперандрогенные состояния</kwd><kwd>акне</kwd><kwd>гирсутизм</kwd><kwd>андрогенетическая алопеция</kwd><kwd>синдром поликистозных яичников</kwd><kwd>андрогены</kwd><kwd>комбинированные оральные контрацептивы</kwd><kwd>антиандрогены</kwd><kwd>обзор</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Igumnov IA, Sharifulin EM, Belenkaya LV, et al. Chronic systemic inflammation in pathways of metabolic syndrome associated with hyperandrogenism (review). Pathogenesis. 2020;18(3):12–18. doi: 10.25557/2310-0435.2020.03.12-18 EDN: GBLLMJ</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Torchen LC, Wu M, Thompson B, Beaudouin A. Polycystic ovary syndrome: origins and implications: the significance of functional adrenal hyperandrogenism in polycystic ovary syndrome across the lifespan. Reproduction. 2025;169(6):e250091. doi: 10.1530/REP-25-0091 EDN: ENHUBM</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Gryazeva NV, Tamrazova AV, Alexandrova EB. Hormones as an additional therapeutic target in acne care. Kremlin medicine. Clinical bulletin. 2022;(1):66–70. doi: 10.26269/k15e-vj12 EDN: SIDUIC</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bakirzhan MA, Kozhemzharova MK, Kuanyshbaeva GS, et al. A clinical case of hyperandrogenism in a patient with Itsenko-Cushing’s disease. Reproductive medicine. 2024;(1):131–137. (In Russ.) doi: 10.37800/rm.1.2024.131-137 EDN: PKSVAY</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Taganov AV, Tikhomirov TA, Rozhdestvenskaya OA, et al. Obesity as a factor contributing to pathogenesis of skin diseases. Endocrinology: news, opinions, training. 2021;10(4):52–61. doi: 10.33029/2304-9529-2021-10-4-52-61 EDN: NBQRLP</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Тeede HJ, Misso ML, Costello MF; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–379. doi: 10.1016/j. fertnstert.2018.05.004 EDN: YJUKHZ</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hirschberg AL. Approach to investigation of hyperandrogenism in a postmenopausal woman. J Clin Endocrinol Metab. 2023;108(5):1243–1253. doi: 10.1210/clinem/dgac673 EDN: RIOHAE</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Xing C, Zhang J, Zhao H, He B. Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment. Int J Womens Health. 2022;14:91–105. doi: 10.2147/IJWH.S344542 EDN: EGWKMK</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Chaudhary H, Patel J, Jain NK, Joshi R. The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis. J Ovarian Res. 2021;14(1):125 doi: 10.1186/s13048-021-00879-w EDN: QXULJS</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tabatabaie SF, Salahshoorifar I, Pouresmaeili F, et al. Association between IL-6 -174 G/C (rs1800795) and IL-1A -889 C/T (rs1800587) cytokine variants with polycystic ovary syndrome in Iranian women: a case-control study. Gene. 2025;933:148906. doi: 10.1016/j.gene.2024.148906</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Eser B, Taskin MI, Hismiogullari AA, et al. The effects of IL-1A and IL-6 genes polymorphisms on gene expressions, hormonal and biochemical parameters in polycystic ovary syndrome. J Obstet Gynaecol. 2017;37(3):358–362. doi: 10.1080/01443615.2016.1256966</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Meczekalski B, Szeliga A, Maciejewska-Jeske M, et al. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism. Gynecol Endocrinol. 2021;37(8):677–682. doi: 10.1080/09513590.2021.1903419 EDN: ALYTMF</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Brown RJ, Joseph J, Cochran E, et al. Type B insulin resistance masquerading as ovarian hyperthecosis. J Clin Endocrinol Metab. 2017;102(6):1789–1791. doi: 10.1210/jc.2016-3674</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Liu Y, Yao ZX, Papadopoulos V. Cytochrome P450 17alpha hydroxylase/17,20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells. Mol Endocrinol. 2005;19(7):1918–31. doi: 10.1210/me.2004-0271</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hammond GL. Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. J Endocrinol. 2016;230(1):R13–25. doi: 10.1530/JOE-16-0070</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Li T, Mo H, Chen W, et al. Role of the PI3K-Akt signaling pathway in the pathogenesis of polycystic ovary syndrome. Reprod Sci. 2017;24(5):646–655. doi: 10.1177/1933719116667606 EDN: QCOXMK</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Dedov II, Melnichenko GA, editors. Endocrinology: national guidelines. 2nd revised and updated. Moscow: GEOTAR-Media; 2016. 1112 p. (In Russ.) EDN: XQKVZA</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Burdea L, Sharma L, Mendez MD. 21-Hydroxylase deficiency [2025 Jan 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Arnaldi G, Martino M. Androgens in Cushing’s syndrome. Front Horm Res. 2019;53:77–91. doi: 10.1159/000494904 EDN: MWUGBT</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Torchen LC, Wu M, Thompson B, Beaudouin A. Polycystic ovary syndrome: origins and implications: the significance of functional adrenal hyperandrogenism in polycystic ovary syndrome across the lifespan. Reproduction. 2025;169(6):e250091. doi: 10.1530/REP-25-0091 EDN: ENHUBM</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Bendarska-Czerwińska A, Zmarzły N, Morawiec E, et al. Endocrine disorders and fertility and pregnancy: an update. Front Endocrinol (Lausanne). 2023;13:970439. doi: 10.3389/fendo.2022.970439 EDN: SSBSUU</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Rojewska P, Meczekalski B, Bala G, et al. From diagnosis to treatment of androgen-secreting ovarian tumors: a practical approach. Gynecol Endocrinol. 2022;38(7):537–542. doi: 10.1080/09513590.2022.2083104 EDN: QMWNVQ</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kalfoutzou A, Petroulakis P, Mylonakis A, et al. Adrenocortical carcinoma with dual androgen and cortisol secretion. Folia Medica. 2025;67(1):e130505. doi: 10.3897/folmed.67.e130505 EDN: BWSIAQ</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Zhou WB, Chen N, Li CJ. A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman. BMC Endocr Disord. 2019;19(1):14. doi: 10.1186/s12902-019-0342-y EDN: PVFOUE</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Sharma A, Welt CK. Practical approach to hyperandrogenism in women. Med Clin North Am. 2021;105(6):1099–1116. doi: 10.1016/j.mcna.2021.06.008 EDN: JCYHKU</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Tsallagova EV, Generalov VO, Sadykov TR. Hyperandrogenism as a side effect of anticonvulsants. Epilepsy and paroxysmal conditions. 2018;10(2):43–50. doi: 10.17749/2077-8333.2018.10.2.043-050 EDN: XWBVKX</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Shamseddin M, De Martino F, Constantin C, et al. Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. EMBO Mol Med. 2021;13(7):e14314. doi: 10.15252/emmm.202114314 EDN: ECWODT</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Kotzé J, Richardson A. Looking ’acceptably’ feminine: a single case study of a female bodybuilder’s use of steroids. Performance Enhancement &amp; Health. 2020;8(2-3):100174. doi: 10.1016/j.peh.2020.100174</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Polat S, Karaburgu S, Unluhizarci K, et al. The role of androgen receptor CAG repeat polymorphism in androgen excess disorder and idiopathic hirsutism. J Endocrinol Invest. 2020;43(9):1271–1281. doi: 10.1007/s40618-020-01215-7</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Weintrob N, Eyal O, Slakman M, et al. Correction: the effect of CAG repeats length on differences in hirsutism among healthy Israeli women of different ethnicities. PLoS ONE. 2018;13(8):e0203181. doi: 10.1371/journal.pone.0203181</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Arning L, Ocklenburg S, Schulz S, et al. Handedness and the X chromosome: the role of androgen receptor CAG-repeat length. Sci Rep. 2015;5:8325. doi: 10.1038/srep08325</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Zuelfakkar NM, Ragab NF, Shehab A, Nagy M. The association of cytosine-adenine-guanine repeat polymorphism in the androgen receptor gene with nodulocystic acne in Egyptian patients. Int J Res Dermatol. 2023;9(4):161–169. doi: 10.18203/issn.2455-4529.IntJResDermatol20231823</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Khan AF, Karami S, Peidl AS, et al. Androgen receptor in hormone receptor-positive breast cancer. Int J Mol Sci. 2023;25(1):476. doi: 10.3390/ijms25010476 EDN: AXHIWA</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520. doi: 10.1210/er.2015-1104</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Fabbrocini G, Cantelli M, Masarà A, et al. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4(4):203–211. doi: 10.1016/j.ijwd.2018.05.001</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Chan L, Cook DK. Female pattern hair loss. Aust J Gen Pract. 2018;47(7):459–464. doi: 10.31128/AJGP-02-18-4498</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Bienenfeld A, Azarchi S, Lo Sicco K, et al. Androgens in women: androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497–1506. doi: 10.1016/j.jaad.2018.08.062 EDN: VQSYEU</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Kasumagic-Halilovic E. Trichoscopic findings in androgenetic alopecia. Med Arch. 2021;75(2):109–111. doi: 10.5455/medarh.2021.75.109-111 EDN: YTTPJF</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Snarskaya ES, Kochubeeva PA. Acanthosis nigricans. Russian journal of skin and venereal diseases. 2015;18(5):13–15. EDN: UXLMZN</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Lewin Z, Vitek WS, O’Malley W, Astapova O. Resolution of hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN) syndrome after sleeve gastrectomy. JCEM Case Rep. 2023;1(1):luac030. doi: 10.1210/jcemcr/luac030 EDN: IWBBBS</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Adalsteinsson JA, Kaushik S, Muzumdar S, et al. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020;29(5):481–489. doi: 10.1111/exd.14091 EDN: PDRPJE</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Yusupova LA, Yunusova EI, Garayeva ZS, et al. Seborrheic dermatitis: pathogenetic aspects, clinical forms and therapy of patients. The Practitioner. 2019;(8):48. EDN: VEYEVI</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Donbaloğlu Z, Tuhan H, Çoban ÖG, et al. Hyperandrogenism correlates with psychological symptoms in adolescents with polycystic ovary syndrome. Clin Pediatr Endocrinol. 2022;31(2):68–76. doi: 10.1297/cpe.2022-0010 EDN: POMEDU</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. doi: 10.1093/humrep/deh098</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Teede HJ, Tay CT, Laven JJ, et al. International PCOS Network. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43–G64. doi: 10.1093/ejendo/lvad096 EDN: CUWYIB</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Mokrysheva NG, Melnichenko GA, Adamyan LV, et al. Russian clinical practice guidelines “Congenital adrenal hyperplasia”. Obesity and metabolism. 2021;18(3):345–382. doi: 10.14341/omet12787 EDN: ABGNUO</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Ilovaiskaya IA. Hyperandrogenic disorders and female diseases: differential diagnosis and treatment approaches. Doctor.Ru. 2018;(6):49–55. doi: 10.31550/1727-2378-2018-150-6-49-55 EDN: OVXHJZ</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Bernárdez C, Molina-Ruiz AM, Requena L. Histologic features of alopecias–part I: nonscarring alopecias. (In English, Spanish). Actas Dermosifiliogr. 2015;106(3):158–167. doi: 10.1016/j.ad.2014.07.006</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Singh S, Pal N, Shubham S, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(4):1454. doi: 10.3390/jcm12041454 EDN: ILAAPJ</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Chernukha GE, Miroshina ED, Kuznetsov SYu, Ivanov IA. Body mass index, body composition, and metabolic profile of patients with polycystic ovary syndrome. Obstetrics and gynecology. 2021;(10):103–111. doi: 10.18565/aig.2021.10.103-111 EDN: CUQUMC</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Grandi G, Del Savio MC, Facchinetti F. The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism. Expert Rev Clin Pharmacol. 2021;14(2):211–224. doi: 10.1080/17512433.2021.1878876 EDN: GWLPIM</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Bahaeldein E, Brassill MJ. Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women. Endocrinol Diabetes Metab Case Rep. 2018;2018:18-0084. doi: 10.1530/EDM-18-0084</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Amiri M, Ramezani Tehrani F, Nahidi F, et al. Comparing the effects of combined oral contraceptives containing progestins with low androgenic and antiandrogenic activities on the hypothalamic-pituitary-gonadal axis in patients with polycystic ovary syndrome: systematic review and meta-analysis. JMIR Res Protoc. 2018;7(4):e113. doi: 10.2196/resprot.9024</mixed-citation></ref></ref-list></back></article>
